Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130208 · ClinicalTrials.gov registry record · Phase 3
Effect of Sulodexide in Early Diabetic Nephropathy
A Phase 3 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,056
- Enrollment target
NCT00130208 is a Phase 3 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 1,056 participants.
The verdict
NCT00130208, a Phase 3 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,056 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
Interventions
- DRUG Placebo
- DRUG Sulodexide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130208
The ClinicalTrials.gov registry entry for NCT00130208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00130208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130208 about?
NCT00130208 is a clinical study titled "Effect of Sulodexide in Early Diabetic Nephropathy". The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
What is the current status of trial NCT00130208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,056 participants. The study started on 2005-08. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00130208?
The interventions under investigation include: Placebo (DRUG), Sulodexide (DRUG).
Who is sponsoring clinical trial NCT00130208?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.